Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 52 clinical trials
A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1)

Primary Objective: To confirm the safety and feasibility of canakinumab and spartalizumab (PDR-001) administered using a standard dose / schedule in the neo-adjuvant setting in renal cell carcinoma Secondary Objectives: To assess the immune response to combination canakinumab and spartalizumab To assess anti-tumor activity as measured by pathologic downstaging

clear cell renal cell carcinoma
neutrophil count
nephrectomy
carcinoma
  • 1 views
  • 06 Apr, 2023
  • 1 location
Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy (NivoM)

This trial is designed as a unicenter, single arm phase II trial. The aim of the trial is to test whether prognosis of high-risk Aggressive B cell Lymphoma (ABCL) patients who are in complete remission (CR) post immunochemotherapy can be improved by 2year nivolumab maintenance therapy. Participants will be recruited …

growth factor
neutrophil count
diffuse large b-cell lymphoma
anthracyclines
blood transfusion
  • 2 views
  • 04 Feb, 2022
  • 1 location
A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Part 1 is the dose escalation of APG-115 in combination with label dose of pembrolizumab. Part 2 is phase II design of APG-115 at recommended phase 2 dose (RP2D) in combination with pembrolizumab.

growth factor
LKB1
lung adenocarcinoma
metastatic melanoma
pembrolizumab
  • 34 views
  • 04 Oct, 2022
  • 19 locations
Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation (CLL-RT1)

The aim of the CLL-RT1 trial is to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK inhibitor plus tislelizumab (BGB-A317), a PD1 inhibitor for treatment of patients with Richter Transformation

  • 1 views
  • 28 Feb, 2022
  • 12 locations
Metformin for Chemoprevention of Lung Cancer in High Risk Obese Individuals

This phase II trial determines the effect of metformin extended release on the risk for developing lung cancer in overweight/obese patients that are at high-risk for developing lung cancer. Metformin is widely used to treat type II diabetes and has a long history of safety and minimal side effects. At …

neutrophil count
diabetes
bronchoscopy
lung cancer
EGFR
  • 0 views
  • 12 Oct, 2022
  • 2 locations
Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC

The purpose of this study is to explore the efficacy and safety of toripalimab combined with anlotinib and SBRT for non-driver gene mutation untreated brain metastases non-small Cell Lung Cancer.

neutrophil count
adjuvant chemotherapy
ROS1
proto-oncogene tyrosine-protein kinase ros
EGFR
  • 0 views
  • 06 Dec, 2021
  • 1 location
MRD-guided Treatment in NPM1mut AML Patients (PEMAZA)

Evaluation the safety and efficacy of Pembrolizumab (PEM) when administered in combination with standard Azacitidine (AZA) in nucleophosmin (NPM1) mutated AML patients with molecular relapse defined by the presence of measurable residual disease (MRD).

azacitidine
anthracyclines
cell transplantation
cytarabine
remission
  • 2 views
  • 04 Oct, 2022
  • 11 locations
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patient With Advanced Cancer

This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, PK, and PD profiles of AGEN2373 as a monotherapy and in combination with botensilimab (also known as AGEN1181), and to assess the maximum tolerated dose (MTD) in subjects with advanced solid tumors.

solid neoplasm
neutrophil count
bladder cancer
renal function
squamous cell carcinoma
  • 20 views
  • 04 Oct, 2022
  • 8 locations
An Open-Label, Dose-Escalation Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Modakafusp Alfa (TAK-573) as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors

This study has 2 phases. The main aims of Phase 1b are: to check for side effects from modakafusp alfa in adults with locally advanced or metastatic solid tumors. to learn how much modakafusp alfa adults can receive without getting any major side effects from it. The main aims of …

denosumab therapy
bone scan
immunomodulators
BRAF
metastatic cutaneous melanoma
  • 62 views
  • 24 Oct, 2022
  • 15 locations
The Efficacy of T-regulatory Cell Depletion With E7777 Combined With Immune Checkpoint Inhibitor, Pembrolizumab, in Recurrent or Metastatic Solid Tumors: Phase I/II Study

Epithelial ovarian cancer (OC) is the most lethal gynecologic cancer: nearly 22,000 women are diagnosed with OC in the US annually and 63% are expected to die from their disease. The 5-year overall survival rate is unacceptably low at 20-30%, with > 50% of patients experiencing recurrence of their disease. …

  • 0 views
  • 29 Oct, 2022
  • 1 location